Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.

Eric P Brass Roger J Lewis Raymond Lipicky James Murphy William R Hiatt

Clin Pharmacol Ther

Department of Medicine, Section of Vascular Medicine, University of Colorado Health Sciences Center, Colorado Prevention Center, and National Jewish Medical and Research Center, Denver, 80203, USA.

Published: March 2006

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.clpt.2005.11.012	DOI Listing

Publication Analysis

Top Keywords

risk assessment

assessment drug

drug development

development symptomatic

symptomatic indications

indications framework

framework prospective

prospective exclusion

exclusion unacceptable

unacceptable cardiovascular

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!